Alagille Syndrome Clinical Trial
— LEAPOfficial title:
Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
The goal of this observational study is to evaluate the long-term safety and clinical outcomes of Livmarli prescribed to patients with Alagille Syndrome (ALGS).
Status | Recruiting |
Enrollment | 50 |
Est. completion date | September 20, 2028 |
Est. primary completion date | September 20, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - A clinically and/or genetically confirmed ALGS diagnosis - Participant prescribed Livmarli Exclusion Criteria: - Refusal to provide informed consent/assent (if required by the local IRB) - Previously or currently on Livmarli through participation in a clinical study or expanded access program - Participants who have previously received an SBD or LT - Any condition or abnormalities that, in the opinion of the investigator, may interfere with the participant participating in or completing the study - Participants who have received an investigational drug within 30 days of the first dose of Livmarli |
Country | Name | City | State |
---|---|---|---|
United States | Children's Healthcare of Atlanta - Emory University School of Medicine | Atlanta | Georgia |
United States | Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado | Aurora | Colorado |
United States | Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology | Kansas City | Missouri |
United States | Children's Hospital Los Angeles CHLA | Los Angeles | California |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | Children Hospital of Pittsburgh | Pittsburgh | Pennsylvania |
United States | Oregon Health and Science University, Division of Pediatric Gastroenterology, Department of Pediatrics | Portland | Oregon |
United States | University of Utah, Division of Pediatric Gastroenterology, Hepatology and Nutrition | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Mirum Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Long-term clinical outcome events | The dates, and reasons for the following first events (of this first endpoint) will be collected: Surgical Biliary Diversion (SBD), Liver Transplant (LT), and all-cause mortality. In addition, manifestations of clinically evident portal hypertension will be captured during each interval event assessments. | Long-term clinical outcomes (SBD, LT, portal hypertension, all-cause mortality) up to 180 days after discontinuation of Livmarli will be recorded. | |
Primary | Liver Transplant Waitlist Status | LT waitlist status will be collected, including when placed on or removed from an LT waitlist. | LT waitlist status will be collected at enrollment and every 6 months for 5 years. | |
Primary | Assessment of Height | Height will be collected both at the time the participant started Livmarli and at the time of enrollment in the study. Subsequent height will be collected for up to 5 years.
Height z-score (centimeters) will be assessed and reported every year for 5 years. |
Height z-score (centimeters) will be collected every year for 5 years. | |
Primary | Assessment of Weight | Weight will be collected both at the time the participant started Livmarli and at the time of enrollment in the study. Subsequent weight will be collected for up to 5 years.
Weight z-score (kilograms) will be assessed and reported every year for 5 years. |
Weight z-score (kilograms) will be collected every year for 5 years. | |
Primary | Incidence of Clinical Events Potentially Related to Fat-Soluble Vitamin Deficiencies | Bleeding events (including all gastrointestinal [GI] or non-GI bleeding requiring hospitalization, emergency department care, or transfusion) and fracture events will be reported. | The incidence of events will be assessed and reported every year for 5 years. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04729751 -
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
|
Phase 2 | |
Active, not recruiting |
NCT05035030 -
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
|
Phase 3 | |
Completed |
NCT02160782 -
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
|
Phase 2 | |
Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
Suspended |
NCT00571272 -
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
|
||
Completed |
NCT02057692 -
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT02922751 -
FibroScanā¢ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
Completed |
NCT00001642 -
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome
|
N/A | |
Recruiting |
NCT05488067 -
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
|
Phase 4 | |
Completed |
NCT04674761 -
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
|
Phase 3 | |
Completed |
NCT02117713 -
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
|
Phase 2 | |
Completed |
NCT02131623 -
Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
|
||
Completed |
NCT02963077 -
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
|
Phase 1 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Completed |
NCT03082937 -
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02047318 -
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
|
Phase 2 | |
Completed |
NCT01903460 -
Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
|
Phase 2 | |
Completed |
NCT01515631 -
Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
|
||
Enrolling by invitation |
NCT05846854 -
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
|
N/A | |
Approved for marketing |
NCT04530994 -
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
|